Biotech & Pharma

StockWatch: Abivax Survives a Roller Coaster Week

25 sec read9 views0 listens

Biotech firm Abivax faced stock volatility after announcing positive Phase III results for its ulcerative colitis drug candidate, obefazimod, amid investor concerns over reported malignancies. Despite the safety signal, analysts highlighted the drug's strong efficacy and potential to outperform existing treatments. This situation underscores the delicate balance between efficacy data and safety concerns in pharmaceutical development.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

The side effects no one reported: How Reddit and AI are changing drug safety

Researchers at the University of Pennsylvania are utilizing large language models to analyze over 400,000 Reddit posts to identify previously unreported side effects of GLP-1 weight-loss drugs. This demonstrates the growing utility of AI in processin...

Ali Nemati

Biotech & Pharma2 days ago29 sec read

Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization

Bio-Techne and Refeyn have launched a combined workflow that integrates imaged capillary isoelectric focusing with mass photometry for the characterization of bispecific antibodies. This solution allows researchers to directly correlate charge varian...

Ali Nemati

Biotech & Pharma2 days ago31 sec read

A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News

Eli Lilly has signed a $1.9 billion agreement with Ascidian Therapeutics to advance a pipeline of RNA exon editors specifically targeting inherited kidney diseases. This massive investment highlights a growing industry focus on high-precision genetic...

Ali Nemati

Biotech & Pharma2 days ago32 sec read

STAT+: Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

The FDA is reviewing its expedited drug review program following feedback from patient groups and companies, with many urging a pause for more public input. In parallel, the FDA has initiated a safety study of the mifepristone abortion pill, which co...

Ali Nemati

Legal & Policy3 days ago32 sec read

Court rules against cell service providers over right to jury trial in FCC proceedings

The Supreme Court has ruled against AT&T and Verizon, upholding the FCC's authority to impose sanctions for telecommunications law violations without requiring an initial jury trial. The Court determined that the Seventh Amendment's right to a ju...

Ali Nemati

StockWatch: Abivax Survives a Roller Coaster Week

Related Articles

The side effects no one reported: How Reddit and AI are changing drug safety

Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization

A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News

STAT+: Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

Court rules against cell service providers over right to jury trial in FCC proceedings